SCHEMBL12667142

SCHEMBL12667142

CCOC(=O)C1CC(=O)N(C)C1

nearest known ligand 0.67

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.67
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 5/20 0.44
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGD P15428 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
GAA P10253 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28956225 1.00 BRD4 (0.67) BRD4SMN1; SMN2ALDH1A1POLBL3MBTL1
SCHEMBL30282498 1.00 BRD4 (0.67) BRD4SMN1; SMN2ALDH1A1POLBL3MBTL1
SCHEMBL15042223 0.87 BRD4 (0.63) BRD4SMN1; SMN2ALDH1A1POLBL3MBTL1
SCHEMBL12368059 0.84 BRD4 (0.59) BRD4SMN1; SMN2ALDH1A1L3MBTL1MAPT
SCHEMBL3826958 0.84 BRD4 (0.59) BRD4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1362127 0.83 BRD4 (0.63) BRD4SMN1; SMN2ALDH1A1L3MBTL1HPGD
SCHEMBL6220495 0.83 ALDH1A1 (0.51) BRD4SMN1; SMN2ALDH1A1MAPTKMT2A
SCHEMBL12667411 0.83 L3MBTL1 (0.55) BRD4SMN1; SMN2ALDH1A1POLBL3MBTL1
SCHEMBL3823508 0.83 BRD4 (0.58) BRD4SMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL31309706 0.82 ALDH1A1 (0.47) BRD4SMN1; SMN2ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746963-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
WO-2025017045-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2025-01-23 WO disclosed
CN-115551841-A Azetidin-3-ylcarbinol derivatives as modulators of the CCR6 receptor 爱杜西亚药品有限公司 2022-12-30 CN disclosed
EP-2734180-B1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES OREAL (FR) 2021-03-31 EP disclosed
EP-2579841-B1 COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED WITH AN ESTER OR AMIDE RADICAL, AND AT LEAST ONE PIGMENT OR DIRECT DYE, FOR DYEING KERATIN MATERIALS ORÉAL L (FR) 2016-09-14 EP disclosed
US-20140294743-A1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES L'OREAL (FR) 2014-10-02 US disclosed
US-20140294743-A1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES L'OREAL (FR) 2014-10-02 US disclosed
US-8771376-B2 Composition comprising at least one 2-pyrrolidone functionalized with an ester or amide radical, and at least one pigment or direct dye, for dyeing keratin materials L'OREAL (FR) 2014-07-08 US disclosed
US-8771376-B2 Composition comprising at least one 2-pyrrolidone functionalized with an ester or amide radical, and at least one pigment or direct dye, for dyeing keratin materials L'OREAL (FR) 2014-07-08 US disclosed
US-20130152314-A1 COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED WITH AN ESTER OR AMIDE RADICAL, AND AT LEAST ONE PIGMENT OR DIRECT DYE, FOR DYEING KERATIN MATERIALS L'OREAL (FR) 2013-06-20 US disclosed
WO-2011054388-A1 COSMETIC COMPOSITIONS COMPRISING AN ESTER DERIVED FROM 4-CARBOXY-2-PYRROLIDINONE AND A LIPOPHILIC SCREENING AGENT; USE OF SAID DERIVATIVE AS A SOLVENT FOR A BENZOPHENONE LIPOPHILIC SCREENING AGENT L'OREAL (FR) 2011-05-12 WO disclosed
US-20100183530-A1 Cosmetic compositions comprising 4-carboxy-2-pyrrolidinone esters and triazine lipophilic UV-screening agents L'OREAL (FR) 2010-07-22 US disclosed
US-20100183529-A1 Cosmetic compositions comprising photostabilized dibenzoylmethane compounds and 2-pyrrolidinone-4- carboxy esters L'OREAL (FR) 2010-07-22 US disclosed
US-20100183529-A1 Cosmetic compositions comprising photostabilized dibenzoylmethane compounds and 2-pyrrolidinone-4- carboxy esters L'OREAL (FR) 2010-07-22 US disclosed
US-20100183530-A1 Cosmetic compositions comprising 4-carboxy-2-pyrrolidinone esters and triazine lipophilic UV-screening agents L'OREAL (FR) 2010-07-22 US disclosed
US-20100143276-A1 Ester solvents derived from 4-carboxy-2-pyrrolidinone formulated into UV-screening cosmetic compositions L'OREAL (FR) 2010-06-10 US disclosed
US-20100143276-A1 Ester solvents derived from 4-carboxy-2-pyrrolidinone formulated into UV-screening cosmetic compositions L'OREAL (FR) 2010-06-10 US disclosed
EP-2193784-A1 Cosmetic compositions containing an ester derivative of 2-pyrrolidinone 4-carboxy and a lipophilic triazine filter, with use of said derivative as a solvent of a lipophilic triazine filter L'OREAL (FR) 2010-06-09 EP disclosed
EP-2193782-A1 Cosmetic composition comprising a dibenzoylmethane derivative and a 2-pyrrolidinone-4-carboxy ester compound; method for the photostabilization of the dibenzoylmethane derivative L'Oreal (FR) 2010-06-09 EP disclosed
EP-2193783-A1 Use of an ester derived from 4-carboxy-2-pyrrolidinone as a solvent in cosmetic compositions; cosmetic compositions containing same L'Oreal (FR) 2010-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130152314-A1 COMPOSITION COMPRISING AT LEAST ONE 2-PYRROLIDONE FUNCTIONALIZED WITH AN ESTER OR AMIDE RADICAL, AND AT LEAST ONE PIGMENT OR DIRECT DYE, FOR DYEING KERATIN MATERIALS KRT18, ADH1A, ADH5 BRD4 446/4885SMN1; SMN2 4418/4885ALDH1A1 40/4885
US-20100183530-A1 Cosmetic compositions comprising 4-carboxy-2-pyrrolidinone esters and triazine lipophilic UV-screening agents TYR, PAH, C1S BRD4 674/4885SMN1; SMN2 4643/4885ALDH1A1 358/4885
US-20100143276-A1 Ester solvents derived from 4-carboxy-2-pyrrolidinone formulated into UV-screening cosmetic compositions FASN, ALOX12, PAH BRD4 1020/4885SMN1; SMN2 3473/4885ALDH1A1 201/4885
US-20140294743-A1 COSMETIC AND/OR DERMATOLOGICAL COMPOSITION CONTAINING A MEROCYANINE DERIVATIVE COMPRISING SPECIFIC POLAR GROUPS CONSISTING OF HYDROXYL- AND ETHER-FUNCTIONALITIES KRT18, LAGE3, TYR BRD4 2467/4885SMN1; SMN2 4825/4885ALDH1A1 1018/4885
US-20100183529-A1 Cosmetic compositions comprising photostabilized dibenzoylmethane compounds and 2-pyrrolidinone-4- carboxy esters CYP1B1, C1S, DDT BRD4 371/4885SMN1; SMN2 4060/4885ALDH1A1 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.